Ping An Biomedical Co., Ltd.
For the period ended Oct 26, 2026. Filed Oct 26, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Oct 26, 2026 · Filed Oct 26, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Statement from Management
Statement from Management
“Building a focused healthcare technology IP reserve is a measured step aligned with our long-term view of the medical market,” said Mr. Pijun Liu, Chief Executive Officer and Chairman of the Board of the Company. “This planned acquisition is a concrete step in our healthcare and biomedical strategy—not a one-off announcement. By combining disciplined capital allocation with rigorous compliance oversight, we aim to assemble core intellectual property that can support the future development and commercialization of related healthcare businesses.”
The Company notes that the planned transaction remains subject to due diligence, the negotiation and execution of definitive agreements, and applicable regulatory and contractual requirements. There can be no assurance that definitive agreements will be entered into or that the acquisition will be completed on the terms contemplated, or at all. The Company may update this announcement following execution of definitive agreements to reflect the final terms.
About Ping An Biomedical Co., Ltd.
Ping An Biomedical Co., Ltd. is a one-stop supply chain management (SCM) service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.